BTBakytkul Toktabayeva

Bakytkul Toktabayeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bakytkul Toktabayeva has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regional Disparities in Registered Autism Spectrum Disorder Cases and Child Psychiatry Workforce Capacity in Kazakhstan, 2015–2025: A Nationwide Registry-Based Study

    by Zhazira Mansharipova, Assiya Turgambayeva, Bakytkul Toktabayeva, Aizhan Abylgazinova, Gulnara Kapanova, Raikhan Temirkhanova, Danara Imanmadiyeva, Marzhan Dauletyarova, Aigul Utegenova, Akmaral Mussakhanova

    Background/Objectives: Newly registered autism spectrum disorder (ASD) cases in Kazakhstan have increased, but population-standardized regional variation and its relation to child psychiatry workforce capacity have not been described. Methods: This retrospective ecological study used annual psychiatric service reports (Form 10-f, Ministry of Health) for 2015–2025, including newly registered cases coded F84.0, F84.1 and F84.5 among children aged 0–17 years. Rates per 100,000 children were calculated nationally and for 16 historical-boundary regions. The national trend was modeled using negative binomial regression and regional inequality using the Gini coefficient. Results: The national rate of newly registered ASD cases increased from 3.9 to 63.5 per 100,000 children (average annual rate ratio 1.32, 95% CI 1.31–1.34), whereas child psychiatrist density declined from 2.06 to 1.43 per 100,000 children and the ratio of newly registered cases to child psychiatrists increased from 1.9 to 44.3. In 2025, regional rates ranged from 28.7 to 221.4 (Astana) per 100,000 children. The Gini coefficient of regional rates decreased from 0.64 to 0.32. Conclusions: Registered ASD cases increased markedly while child psychiatrist density declined, and registration rates varied substantially between regions. These data describe registration rather than prevalence, and regional estimates are subject to uncertainty in population denominators.

  • Open Access

    THE CONDITION OF THE VASCULAR ENDOTHELIUM IN CHILDREN WITH COVID-19 AND BRONCHO-OBSTRUCTIVE SYNDROME

    by A.A. Shakirova, B.ZH. Toktabayeva, A.S. Orazalina, A.ZH. Abylgazinova, K.SH. Amrenova, K.D. Abayeva, G.M. Zhangaliyeva

    Introduction: The impact of SARS-CoV-2 infection on the human organism has proven to be more diverse than that of previously known viral infections. However, the full spectrum of the long-term consequences of the disease, especially in children, has not been thoroughly studied. One key area of concern is the development of broncho-obstructive syndrome (BOS) as a post-COVID-19 complication, which involves airway inflammation and hyperreactivity. This study investigates the relationship between endothelial dysfunction and BOS in pediatric patients following SARS-CoV-2 infection. Objective: To explore the endothelial status in children with SARS-CoV-2 infection and its association with the development of BOS, and to assess the role of endothelial dysfunction markers—circulating endothelial cells (CECs), endothelin-1, and nitric oxide metabolites—in this context. Methods: A retrospective study was conducted between 2020 and 2022, involving 486 children. The study included two primary groups: (1) Control: Healthy children with no history of SARS-CoV-2 infection or BOS; children with SARS-CoV-2 infection but no BOS, and (2) Main: Children with BOS but no SARS-CoV-2 infection; children with SARS-CoV-2 infection followed by the development of BOS. Endothelial function was assessed by measuring levels of CECs, endothelin-1, and nitric oxide metabolites. Results: The study found significantly elevated CECs and endothelin-1 levels, along with decreased nitric oxide metabolites, in children who developed BOS following SARS-CoV-2 infection. The highest levels of endothelial dysfunction markers were observed in this group, suggesting a synergistic effect of SARS-CoV-2 infection and BOS on endothelial damage. Notably, 64.3% of children in this group exhibited elevated CEC levels, reflecting severe endothelial dysfunction. Endothelin-1 levels were also significantly higher in children with BOS after SARS-CoV-2 infection (0.46 ± 0.02 fmol/mL) compared to healthy controls and children with BOS without a history of SARS-CoV-2 infection. These findings highlight the critical role of endothelial dysfunction in the pathogenesis of post-COVID-19 respiratory complications. Conclusion: SARS-CoV-2 infection contributes to significant endothelial dysfunction in children, particularly in those who develop BOS. The combination of SARS-CoV-2 infection and BOS exacerbates endothelial damage, which likely plays a critical role in the pathogenesis of post-COVID-19 respiratory complications. These findings suggest the need for further research into therapeutic strategies aimed at correcting endothelial dysfunction, potentially improving outcomes for pediatric patients suffering from long-term respiratory sequelae following COVID-19. Введение: Воздействие инфекции SARS-CoV-2 на человеческий организм оказалось более разнообразным, чем у ранее известных вирусных инфекций. Однако полный спектр долгосрочных последствий заболевания, особенно у детей, еще не был тщательно изучен. Одной из ключевых проблем является развитие бронхообструктивного синдрома (БОС) как постковидного осложнения, которое включает воспаление дыхательных путей и гиперреактивность. Это исследование направлено на изучение связи между эндотелиальной дисфункцией и БОС у детей после инфекции SARS-CoV-2, и на определение роли маркеров эндотелиальной дисфункции - циркулирующих эндотелиальных клеток (ЦЭК), эндотелина-1 и метаболитов оксида азота - в этом контексте. Методы: Ретроспективное исследование было проведено в период с 2020 по 2022 год и охватило 486 детей. Исследование включало две основные группы: (1) Контрольная группа: здоровые дети, не имеющие истории инфекции SARS-CoV-2 или БОС; дети с инфекцией SARS-CoV-2, но без БОС, и (2) Основная группа: дети с БОС, но без инфекции SARS-CoV-2; дети с инфекцией SARS-CoV-2, за которой последовало развитие БОС. Функция эндотелия оценивалась путем измерения уровней ЦЭК, эндотелина-1 и метаболитов оксида азота. Результаты: Исследование показало значительное повышение уровней ЦЭК и эндотелина-1, а также снижение метаболитов оксида азота у детей, развивших БОС после инфекции SARS-CoV-2. Наибольшие уровни маркеров эндотелиальной дисфункции были обнаружены в этой группе, что свидетельствует о синергетическом эффекте инфекции SARS-CoV-2 и БОС на повреждение эндотелия. Особенно важно, что 64,3% детей в этой группе продемонстрировали повышенные уровни ЦЭК, что отражает тяжелую эндотелиальную дисфункцию. Уровни эндотелина-1 также были значительно выше у детей с БОС после инфекции SARS-CoV-2 (0,46 ± 0,02 фмоль/мл) по сравнению...

  • Open Access

    THE IMPACT OF GENE MUTATIONS IN THYROID CANCER: A REVIEW

    by A.KH. Yerketayeva, Zh.B. Mussazhanova, Zh.Y. Kozykenova, L.A. Pak, Z.D. Dushimova, B.ZH. Toktabayeva, L.K. Zhazykbayeva, A.M. Rakhmankulova

    Introduction: Thyroid cancer is a common endocrine malignancy, with DICER1 mutations emerging as significant contributors to its development and progression. The identification of these mutations through molecular genetic analysis, particularly in poorly differentiated thyroid carcinomas and pediatric follicular thyroid carcinomas, has provided valuable insights into the pathophysiological mechanisms underlying the disease. Studies by Volante et al. and Lee et al. have highlighted the importance of genetic testing for DICER1 mutations in guiding clinical management, enabling more precise risk stratification, and tailoring patient-specific therapeutic approaches. Despite these advances, critical gaps remain in our understanding of the full spectrum of DICER1-associated phenotypes and the molecular mechanisms involved. Future research is needed to elucidate the biological pathways influenced by DICER1 mutations and to explore the potential for targeted therapies. Additionally, developing strategies for early detection and personalized treatment plans based on genetic profiles could significantly improve patient outcomes. This reviewaims to analyze publications devoted to the significant role of DICER1 mutations in thyroid cancer. Search strategy: The literature search was performed in the electronic databases PubMed, WoS, Scopus, Google Scholar over the past 10 years: from 2014 to 2024, but information about topic (the Impact of DICER1 Mutations on Thyroid Cancer) was not full. Most of the valuable information related to the problem, found in the databases, was from 2005–2007, 2009, and 2011–2013, and was included in the review. These sources do not fall into the specified depth, but were accepted for analysis because they contain conceptual information. Criteria for inclusion of publications in the review: publications in full text access in Russian and English, bearing statistically confirmed conclusions. Exclusion criteria: abstracts of reports, newspaper publications, paid access articles, personal communications. Results: This review synthesizes current insights into the mechanisms of formation of the DICER1 gene mutation. Despite these advances, there is no complete spectrum of DICER1-related phenotypes and molecular mechanisms involved in this process. Further research is needed to clarify the biological pathways affected by DICER1 mutations and explore the potential of targeted therapies. In addition, the development of early detection strategies and personalized treatment plans based on genetic profiles can significantly improve patient outcomes. This review highlights the need for continued research on DICER1 gene mutations to fully exploit their potential in improving the diagnosis, management, and treatment of thyroid cancer. Conclusions: The presented data allow us to formulate a clinical and pathophysiological approach to the clinic and treatment of thyroid cancer. Conducting genetic analysis for DICER1 gene mutations can lead to the development of personalized and effective treatment plans. The study of DICER1 mutations will improve patient outcomes by improving the approach to the diagnosis and treatment of thyroid cancer. Thus, the detection of the presence of a DICER1 gene mutation in thyroid cancer is an important part in the management of patients with thyroid cancer, which will also improve the outcome of the disease. Введение: Рак щитовидной железы - распространенное эндокринное злокачественное новообразование, в развитии и прогрессировании которого значительную роль играет мутация гена DICER1. Выявление этих мутаций с помощью молекулярно-генетического анализа, особенно в низко дифференцированных карциномах щитовидной железы и детских фолликулярных карциномах щитовидной железы, позволило получить ценные сведения о патофизиологических механизмах, лежащих в основе этого заболевания. Исследования Volante et al. и Lee et al. подчеркнули важность генетического тестирования на мутации DICER1 для руководства клиническим лечением, более точной стратификации риска и подбора терапевтических подходов с учетом индивидуальных особенностей пациента. Целью данного обзора являлась систематизация данных о роли мутаций DICER1 при раке щитовидной железы. Стратегия поиска: Поиск литературы проводился в электронных базах данных PubMed, WoS, Scopus, Google Scholar за последние 10 лет: с 2014 по 2024 год, но информация по теме (влияние мутаций DICER1 на рак щитовидной железы) была неполной. Большая часть ценной информации, описывающей проблему, найденную в базах данных за 2005–2007, 2009, 2011–2013 годы, была включена ввиду отражения основной проблемы темы. Критерии включения публикаций в обзор: публикации в полнотекстовом доступе на русском и английском языках, содержащие статистически подтвержденные выводы. Критерии исключения: тезисы докладов, газетные...